DivestmentMay 14, 2026, 06:12 AM
Moolec Science Reports $129.3M Gain on Subsidiary Deconsolidation
AI Summary
Moolec Science SA reported a significant profit of $92.0 million for the six-month period ended December 31, 2025, primarily driven by a $129.3 million gain from the deconsolidation of its subsidiaries, Bioceres S.A. and Bioceres LLC, following their bankruptcy proceedings. These events, alongside a business combination with Bioceres Group, Nutrecon, and Gentle Tech, have fundamentally altered the company's operational scope and financial position. Despite the reported profit, the company faces a negative working capital position and significant liquidity challenges, raising material uncertainty about its ability to continue as a going concern, though a $6 million credit line has been secured from a major shareholder.
Key Highlights
- Moolec Science recorded a $129.3 million gain on the deconsolidation of Bioceres S.A. and Bioceres LLC.
- The company lost control over Bioceres S.A. and Bioceres LLC due to voluntary bankruptcy proceedings on December 16, 2025.
- Moolec Science also lost control over Theo I SCSp due to the initiation of bankruptcy proceedings on December 31, 2025.
- The company completed a business combination with Bioceres Group, Nutrecon, and Gentle Tech on June 16, 2025.
- Reported a profit of $92.0 million for the six-month period ended December 31, 2025, compared to a $36.8 million loss in 2024.
- Basic profit per share from discontinued operations was $108.89 for the six-month period ended December 31, 2025.
- Basic loss per share from continuing operations was $(13.92) for the six-month period ended December 31, 2025.
- The Group reported a negative working capital position as of December 31, 2025, indicating insufficient financial resources.
- Secured a credit line of up to $6 million from Granosur Holding Limited, a major shareholder, on November 28, 2025.